Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Coding Corner Question: Physical Examination with Infliximab Infusion

From the College  |  Issue: July 2016  |  July 14, 2016

A 12-year-old male established patient with inflammatory bowel disease with associated juvenile spondyloarthropathy returns to the office for a follow-up visit for his infliximab infusion. The patient reports moderate pain in his right hip after walking for extended periods of time or after sports activities. He denies any other joint pain and denies any joint swelling. He has morning stiffness two to three days per week lasting approximately 30 minutes. The patient reports his appetite is great, but does have crampy abdominal pain associated with defecation and loose stools an average of two to three times per week. He is scheduled to see his gastroenterologist in two weeks for follow-up of his Crohn’s disease. The patient denies fever, rashes, chest pain, cough, headaches or allergies. The patient is an 8th grade basketball player and denies missing school due to illness. In addition to infliximab infusions every eight weeks, the patient is on methotrexate, folic acid, sulfasalazine and celecoxib.

The rheumatologist performs a detailed physical examination, which reveals irritability and decreased internal rotation in the right hip. The patient’s sulfasalazine is increased to 750 mg, and he will continue on his other medications. Routine laboratory studies and an X-ray of the patient’s right hip are ordered. Influenza vaccination is recommended, because the patient is on immunosuppressive medications. The patient is to return for follow-up evaluation in six weeks.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The patient then receives an infusion of 350 mg infliximab. The medication is started at 10:05 a.m. and completed at 12:25 p.m.

How should this patient encounter be coded?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Share: 

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodinginfliximabpatient carephysical examPractice Managementrheumatology

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Reading Rheum

    July 1, 2007

    Handpicked Reviews of Contemporary Literature

    Rheumatology Coding Corner Answer: Physical Examination with Infliximab Infusion

    July 14, 2016

    Take the challenge. CPT: 99214-25, 96413, 96415 x 1, J1745 x 35 ICD-10: M07.68, K51.80 ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEBilling Overview It is appropriate to bill for an E/M visit for this day of service along with the infusion procedure. Modifier 25 should be appended to the E/M, indicating that the patient received a significant,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences